BioStock: Cyxone joins forces with leading rheumatoid arthritis expert

18 May 2021 - 10:16

Biotech company Cyxone is in the process of preparing drug candidate Rabeximod for the next clinical stage. Recently, the company announced a collaboration with Professor Costantino Pitzalis, a world leading expert redefining clinical trial design in RA, to advise on the upcoming phase IIb trial. BioStock reached out to professor Pitzalis to hear his view on Rabeximod and what impact the drug candidate potentially can make in the field of rheumatoid arthritis in the current market.

Read the full interview with Professor Costantino Pitzalis at

This is a pressrelease from BioStock Connecting Innovation & Capital.

Provided by: Cision
Nasdaq First North GM (Sweden)
Cyxone AB
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More